Federal and State Laws Relating to Prescribing of Controlled Substances
|
|
|
- Beverly Cook
- 10 years ago
- Views:
Transcription
1 Federal and State Laws Relating to Prescribing of Controlled Substances Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
2 Disclosure No financial or other material conflicts of interest This is not legal advice These comments are not representative of any institution or organization
3 Outline Federal laws on prescribing controlled Florida laws and rules on prescribing controlled Current Florida statistics regarding M&M of controlled substance-related deaths Pharmacology of opiates Proper prescribing of opiates Physician liability for overprescribing controlled
4 Outline Federal laws on prescribing controlled Florida laws and rules on prescribing controlled Current Florida statistics regarding M&M of controlled substance-related deaths Pharmacology of opiates Proper prescribing of opiates Physician liability for overprescribing controlled
5 C-II prescriptions do not have an expiration Florida Rx must be filled within 1yr No refills allowed C-III prescriptions expire 6mos post date written Max of 5 refills within 6mos Physicians who prescribe controlled are required to obtain a DEA certificate Physicians who write or dispense controlled for detoxification must be separately registered for that purpose
6 Outline Federal laws on prescribing controlled Florida laws and rules on prescribing controlled Current Florida statistics regarding M&M of controlled substance-related deaths Pharmacology of opiates Proper prescribing of opiates Physician liability for overprescribing controlled
7 Chronic nonmalignant pain Pain unrelated to cancer which persists beyond the usual course of the disease or the injury that is the cause of the pain or more than 90 days after surgery Fla. Stat. Section controlled substance prescribing
8 Physician requirements 1 Identify as a controlled substance providing practitioner on DOH profile Satisfy medical records req s Conduct and document a physical exam before tx Document current and past tx for pain, inc Rx from prior physicians Show a review of previous medical records (must request them if immediately unavailable) Records must be individualized (no template) Photocopy of gov t-issued photo ID (usually DL) Drugs prescribed
9 Physician requirements 2 Document a tx plan with pt-specific objectives With pt, co-sign controlled substance agreement Discuss abuse and addiction risks with pt Meet with pt no more frequently than q3mos Assess tx Monitor addiction risk Evaluate potential drug-related aberrant behavior Unless certified in pain mgmt, pts with abuse sx must be referred Board-certified pain mgmt physician Addiction medicine specialist Mental health facility for abuse/addiction
10 Physician requirements 3 If referred, physician must document medical justification for ongoing prescriptions After receiving report from consultant, physician must incorporate recs in further tx of pt Exceptions Neoplastic pain may be tx with C-II IV agents without necessitating registration as a controlled substance provider nor does it require abiding by the other reqs Pain prompted by injury that follows its usual course Prescription for indication other than chronic nonmalignant pain (eg, BZD for anxiety)
11 Pain Management Clinics Any location that: Advertises pain mgmt services must register In any month, prescribes opiates, BZDs, barbs, or carisoprodol for tx chronic nonmalignant pain for most of its pts must register Even if the owner/mgmt/business name is the same, each clinic must register separately Physicians generally must own the clinic Exception: if most physicians primarily do surgeries does not have to register Fla. Stat. Section pain-management clinics
12 Physician responsibilities Notify BOOM within 10d of beginning/ending practice in a pain mgmt clinic Comply with the clinic s physical & operational, infx prevention & control, health & safety, QA, and data collection & reporting req s Each DO is responsible for ensuring clinic s compliance with above Pain mgmt clinics must designate a physician as the responsible party for its registration & operational req s
13 March 2010 June 2012 registrations Number of Pain Clinics
14 Training requirements Effective 7/1/12 Successful completion of an AOA- or ACGMEaccredited pain mgmt residency or fellowship Fla. Admin. Code Ann. r. 64B
15 Prior to 7/1/12 (one of the following) 1. Specialty certification in pain medicine 2. Completion of post-graduate pain mgmt training 3. Completion of AOA/ACGME residency in PM&R, anesthesiology, neurology, neurosurgery, or psychiatry 4. Completion of AOA residency in FM, IM, or orthopedics 5. AOA certification in hospice, pall car, or geriatrics 6. Current hospital staff privileges for pain medicine 7. 3yrs of documented full time practice 20hrs/wk each year in pain mgmt 40hrs, live, in-person AMA-I/AOA-Ia CME in pain mgmt
16 Outline Federal laws on prescribing controlled Florida laws and rules on prescribing controlled Current Florida statistics regarding M&M of controlled substance-related deaths Pharmacology of opiates Proper prescribing of opiates Physician liability for overprescribing controlled
17 Drugs Identified in Deceased Persons by Florida Medical Examiners * 5, % 2,710 20% % 1, % 27.9% (2009) 16.3% $3.6B
18 Outline Federal laws on prescribing controlled Florida laws and rules on prescribing controlled Current Florida statistics regarding M&M of controlled substance-related deaths Pharmacology of opiates Proper prescribing of opiates Physician liability for overprescribing controlled
19 Receptor activity Mu Delta Kappa Analgesia Sedation Euphoria Respiratory depression Constipation Physical dependence Analgesia with fewer adverse effects Mild analgesia Less respiratory depression
20 Opioid classification Full agonist Partial agonist Agonistantagonist Antagonist Morphine Buprenorphine Pentazocine Naloxone Fentanyl Butorphanol Naltrexone Oxycodone Nalbuphine Hydrocodone Methadone
21 Opioid comparison Medication Onset Duration Fentanyl patch hrs 72 hrs/patch Equianalgesic dose Hydromorphone mins 4-6 hrs 7.5mg po Methadone mins > 8 hrs Morphine IR mins 3-6 hrs 30mg po MS Contin mins 8-12 hrs 30mg po Kadian mins hrs 30mg po Oxycodone IR mins 4-6 hrs 20mg po Oxycodone CR 1 hr 12 hrs 20mg po Hydrocodone mins 4-6 hrs 30mg po Codeine mins 4-6 hrs 200mg po Meperidine mins 2-4 hrs 300mg po
22 Opioid allergy Phenanthrenes Piperidine/ phenylpiperadine Deiphenylheptanes Morphine Fentanyl* Methadone* Hydromorphone* Meperidine Propoxyphene Oxymorphone* Codeine Hydrocodone Oxycodone*
23 Controlled substance class examples C-II C-III C-IV C-V Codeine Lower dose of codeine Tramadol Lowest dose of codeine Fentanyl Anabolic steroids Chloral hydrate Robitussin-AC Hydrocodone Lower dose of hydrocodone Morphine Ketamine Clorazepate Oxycodone Dronabinol Carisoprodol Methadone GHB Meprobamate Chlordiazepoxide Lomotil Phenergan with codeine Amphetamine Pentobarbital Phentermine Phenobarbital
24 Outline Federal laws on prescribing controlled Florida laws and rules on prescribing controlled Current Florida statistics regarding M&M of controlled substance-related deaths Pharmacology of opiates Proper prescribing of opiates Physician liability for overprescribing controlled
25 Be sensitive to psychological issues Adhere to pain mgmt contract Sincere ongoing communication Consider regular urine drug testing Note signs of abusive behavior Nuisance office calls Lost Rx Early refills CAGE-like screening each visit Adherence to prescription-writing requirements
26 Counterfeit-proof Rx pads Controlled substance Rx must be written on a counterfeit-resistant pad produced by an approved vendor, or electronically prescribed Otherwise, risk of Rx rejection and confiscation /faq/faq.htm
27 Components of a legitimate Rx Legible printed/typed on counterfeit-proof Rx Date in textual format Patient name & address Name and strength of medication Dispense amount in both textual and numeric format Sig: directions should be legibly written out Number of refills, if any DEA number legibly written Signature ink or typed (no signature stamps) Doctor office name and contact information (eg, address, phone)
28 Example Dr. John Smith 1234 Main Street Anytown, Florida Date: February 11, 2014 Patient Name: Jane Smith DOB:05/29/1966 Address: 1111 Center Lane, Anytown, Florida Percocet (5/325) Disp. # 60 (Sixty) Sig: Take one tab by mouth every 6 hours PRN post-op pain No Refills DEA # Signature
29 E-FORCSE Electronic - Florida Online Reporting of Controlled Substances Evaluation program: Florida's Prescription Drug Monitoring Program (PDMP). Created by the 2009 legislature, an initiative to encourage safer prescribing of controlled and to reduce drug abuse and diversion within the State. Operational 9/1/11; Health care practitioner (HCP) access 10/17/11; law enforcement access 11/14/11 Health Information Designs, Inc. developed a database that collects and stores prescribing and dispensing data for controlled in Schedules II, III, and IV. PDMP purpose: to provide information to HCPs to guide their decisions in prescribing and dispensing controlled.
30 Florida s PDMP: As of June 30, Dispensing Records Uploaded 145,696,235 TOTAL Practitioner Registrations 30,339 Total Patient Advisory Reports Requested 19,389,253
31 Fla. Stat. Section , requires reporting to the PDMP each time a controlled substance is dispensed to an individual. Reporting via the electronic system as soon as possible, but not more than 7 days after dispensing. Reporting timeframe ensures that health care practitioners have the most up-to-date information available. E-FORCSE complies with the Health Insurance Portability and Accountability Act (HIPAA).
32 Outline Federal laws on prescribing controlled Florida laws and rules on prescribing controlled Current Florida statistics regarding M&M of controlled substance-related deaths Pharmacology of opiates Proper prescribing of opiates Physician liability for overprescribing controlled
33 Minimum penalty for 1 st violation 6mo license suspension, probation + $10,000 fine Minimum penalty for 2 nd violation 1yr license suspension, probation + $10,000 fine Maximum penalty for either offense License revocation + $10,000 fine
34 Conclusion Medical history & physical exam prior to beginning treatment Detailed medical records are a must Written treatment plan for assessing and monitoring risk Controlled substance agreement Regular follow up as least every three months Referral as necessary
35 Thank you Special thanks to David A. Lips, attorney Hall, Render, Killian, Heath & Lyman, P.C. Indianapolis, IN Joshua D. Lenchus, DO, RPh, FACP, SFHM (off)
Pain Management Regulations Affect More Than Pain Management Specialists January 2012. Of counsel to
Pain Management Regulations Affect More Than Pain Management Specialists January 2012 LINDA A. KEEN MSN, JD, LHCRM LAW OFFICE OF LINDA A. KEEN P.A. TALLAHASSEE, FL Of counsel to Pain Management Regulations
Federal and Florida Laws Related to the Prescribing of Controlled Substances
Federal and Florida Laws Related to the Prescribing of Controlled Substances By David A. Lips Hall Render Killian Heath & Lyman, PC One American Square, Suite 2000 Indianapolis, Indiana 46282 Indiana Osteopathic
Palmer MacKie, MD MS Director, Integrative Pain Program, Eskenazi Department of Medicine, IUSOM
Palmer MacKie, MD MS Director, Integrative Pain Program, Eskenazi Department of Medicine, IUSOM Attorney General s Prescription Drug Abuse Task Force Member AIT Laboratories Advisory Board In 2009, 44%
Opioid Analgesics. Week 19
Opioid Analgesics Week 19 Analgesic Vocabulary Analgesia Narcotic Opiate Opioid Agonist Antagonist Narcotic Analgesics Controlled substances Opioid analgesics derived from poppy Opiates include morphine,
Information for Pharmacists
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
Implementing Prescribing Guidelines in the Emergency Department. April 16, 2013
Implementing Prescribing Guidelines in the Emergency Department April 16, 2013 Housekeeping Note: Today s presentation is being recorded and will be provided within 48 hours. Two ways to ask questions
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
How To Get A Prescription In Rhode Island
Controlled Substance Prescribing Laws, The Prescription Monitoring Program, and Preventing Drug Diversion Michael Halse, PharmD PGY1 Resident Pharmacist South County Hospital and Healthcare System Disclosures
OBJECTIVES. ! Understand the rising epidemic of prescription drug abuse in Wyoming. ! Know how to access and use reports from the WORx program
Full source: Wyoming Survey & Analysis Center (2013). Wyoming Prevention Needs Assessment: Interactive Graphing. Laramie, WY: University of Wyoming. (http://pnasurvey.org) Full Source: Wyoming Department
RULES OF DEPARTMENT OF HEALTH DIVISION OF PAIN MANAGEMENT CLINICS CHAPTER 1200-34-01 PAIN MANAGEMENT CLINICS TABLE OF CONTENTS
RULES OF DEPARTMENT OF HEALTH DIVISION OF PAIN MANAGEMENT CLINICS CHAPTER 1200-34-01 PAIN MANAGEMENT CLINICS TABLE OF CONTENTS 1200-34-01-.01 Purpose 1200-34-01-.06 Notifications 1200-34-01-.02 Definitions
SAFE PAIN MEDICATION PRESCRIBING GUIDELINES
Prescription drug abuse has been declared an epidemic by the Centers for Disease Control. According to 2012 San Diego Medical Examiner data, the number one cause of non-natural death is due to drug overdoses
Clinic Reference Guide
Clinic Reference Guide 2010 Alliance Toxicology LLC PO Box 5000, PMB 190 Rancho Santa Fe, CA 92067 AllianceToxicologyLLCprovidesclinicaldrugtestingservicesforphysicians.Our companyprovidesacomprehensivedrugtestingpanelwhichincludesover40
Prescribers required to check PDMP before first prescription for Controled Substances for new patient.
State, District, or Territory Alabama Arizona Arkansas Colorado Connecticut Delaware Georgia Guam Criteria for Mandatory Enrollment or Query of PDMP Before renewing an Alabama Controlled Substances Certificate,
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN Introduction The Manitoba Prescribing Practices Program (MPPP) recognizes the important role served by physicians in relieving pain and suffering and acknowledges
Visit www.takebackmylife.org to hear more of my story or call 211 for help and treatment options
In high school, I experimented with alcohol and pot. Then I moved on to narcotics and cocaine, which landed me in jail several times. By 25, I was a daily heroin user with a long-term prison sentence.
Arkansas Emergency Department Opioid Prescribing Guidelines
Arkansas Emergency Department Opioid Prescribing Guidelines 1. One medical provider should provide all opioids to treat a patient s chronic pain. 2. The administration of intravenous and intramuscular
2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California FRIDAY, FEBRUARY 6, 2015: 9:30am - 10:30am Opioid Addiction and Buprenorphine Use * Presented by
The TIRF REMS Access program is a Food and Drug Administration (FDA) required risk management program
Subject: Important Drug Warning Announcement of a single shared REMS (Risk Evaluation and Mitigation Strategy) program for all Transmucosal Immediate Release Fentanyl (TIRF) products due to the potential
Who is the DEA? New Narcotic Regulations and How They Affect Your Assisted Living Facility. 2009 DEA Audits. Scheduled/Controlled Drugs
Who is the DEA? New Narcotic Regulations and How They Affect Your Assisted Living Facility Nancy Lamb RPh Good Day Pharmacy DEA- Drug Enforcement Administration This is not the State Health Department
Richard C. Dart, MD, PhD Denver Health & Hospital Authority Professor, University of Colorado School of Medicine
Richard C. Dart, MD, PhD Denver Health & Hospital Authority Professor, University of Colorado School of Medicine Goal: Minimize abuse and diversion (MAD) while providing pain control for patients. A claim
Opioids for Pain Treatment. Opioids for Chronic Pain and Addiction Treatment. Outline for Today. Opioids for pain treatment
Opioids for Chronic Pain and Addiction Treatment Joseph Merrill M.D., M.P.H. University of Washington February 24, 2012 Outline for Today Opioids for pain treatment Trends Problems High dose prescribing
Palliative Medicine, Pain Management, and Hospice. Devon Neale, MD Assistant Professor Dept of Internal Medicine UNM School of Medicine
Palliative Medicine, Pain Management, and Hospice Devon Neale, MD Assistant Professor Dept of Internal Medicine UNM School of Medicine Pall-i- What??? Objectives: Provide information about Palliative Medicine
Update on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
Office-based Treatment of Opioid Dependence with Buprenorphine
Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures
Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients
Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Developed by the Mid Atlantic Renal Coalition and the Kidney End of Life Coalition September 2009 This project was supported,
Testimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013
Testimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013 Chairman Lee, members of the Senate Human Services Committee,
Protecting Your Practice and Patients Tackling Prescription Drug Abuse Accreditation Pharmacists: 0798-0000-12-040-L05-P Nurses: N-764
Page 1 Protecting Your Practice and Patients Tackling Prescription Drug Abuse Accreditation Pharmacists: 0798-0000-12-040-L05-P Nurses: N-764 CE Credit(s) 1.0 contact hour(s) Protecting Your Practice and
OPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School
OPIOIDS Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School Rutgers New Jersey Medical School Fundamentals of Addiction Medicine Summer Series Newark, NJ July 24, 2013
Florida Laws & Rules Osteopathic Medicine
Florida Laws & Rules Osteopathic Medicine Jason D. Winn, PA, Attorney at Law - 850/222-7199 [email protected] ACOI's 2015 Annual Convention & Scientific Sessions October 3, 2015 - TAMPA, FL Disclosure
PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications
PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications Primary Care & Specialist Prescribing Guidelines Introduction Partnership HealthPlan is a County Organized Health System covering
SUBOXONE /VIVITROL WEBINAR. Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12
SUBOXONE /VIVITROL WEBINAR Educational Training tool concerning the Non-Methadone Medication Assisted Treatment Policy that is Effective on 1/1/12 WEBINAR INTRODUCTIONS Cynthia Parsons- Program Manager
Using Buprenorphine in an Opioid Treatment Program
Using Buprenorphine in an Opioid Treatment Program Thomas E. Freese, PhD Director of Training, UCLA Integrated Substance Abuse Programs Director, Pacific Southwest Addiction Technology Transfer Center
Federal Regulations For Prescribing Scheduled Controlled Substances
Federal Regulations For Prescribing Scheduled Controlled Substances HEIT TEMPLATE.PPT 1 Central Principle of Balance With the Use of Controlled Substances Dual imperative of government Establish a system
Getting the best result from Opioid medicine. in the management of chronic pain
Getting the best result from Opioid medicine in the management of chronic pain Your doctor has prescribed you opioid medicine to help you manage your chronic pain. This patient information leaflet gives
Treatment Programs (OMTP)
Sponsored by: Continuing Medical Education Program best practices for Opiate Maintenance Treatment Programs (OMTP) Avoid Abuse, Limit Liability May 8-11, 2012 December 4-7, 2012 Case Western Reserve University
Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist
Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids
Prescription Drug Abuse and Pain Management Clinics 2015 Report to the 109 th Tennessee General Assembly
Prescription Drug Abuse and Pain Management Clinics 2015 Report to the 109 th Tennessee General Assembly Andrea Huddleston, Chief Deputy General Counsel Tennessee Department of Health Office of General
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate
Policy for the issue of permits to prescribe Schedule 8 poisons
Policy for the issue of permits to prescribe Schedule 8 poisons May 2011 Introduction The Victorian Drugs, Poisons and Controlled Substances (DPCS) legislation sets out certain circumstances when a medical
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain Division of Workers Compensation 04.01.2015 Background Opioids
Rationale for Urine Drug Testing (UDT)
Rationale for Urine Drug Testing (UDT) Help to identify drug misuse/addiction Prior to starting opioid treatment Assist in assessing adherence during opioid therapy As requirement of therapy w/ an opioid
Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
CHAPTER 2010-211. Committee Substitute for Committee Substitute for Senate Bill No. 2272 and Committee Substitute for Senate Bill No.
CHAPTER 2010-211 Committee Substitute for Committee Substitute for Senate Bill No. 2272 and Committee Substitute for Senate Bill No. 2722 An act relating to controlled substances; amending s. 456.037,
EPIDEMIC 4.6 % OF INDIVIDUALS 18 25 USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
Use of Buprenorphine in the Treatment of Opioid Addiction
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
Prescription drug abuse trends. Minnesota s Prescription Monitoring Program. Minnesota Rural Health Conference June 25, 2013 Duluth
Prescription drug abuse trends Minnesota s Prescription Monitoring Program Carol Falkowski Drug Abuse Dialogues www.drugabusedialogues.com Barbara Carter, Manager MN Board of Pharmacy www.pmp.pharmacy.state.mn.us
ARCHIVED BULLETIN. Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E
BULLETIN INTELLIGENCE Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III drug has been made available for use
Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)
Appendix D: Urine Drug Testing for Monitoring Opioid Therapy i. Monitoring opioid therapy with urine drug testing (UDT) ii. UDT algorithm for monitoring opioid therapy iii. UDT clinical vignettes iv. Frequently
Naloxone treatment of opioid overdose
Naloxone treatment of opioid overdose Opioids Chemicals that act in the brain to relieve pain, often use to suppress cough, treat addiction, and provide comfort After prolonged use of opioids, increasing
OPIOID CONVERSIONS. 2. Add a rescue doses (IR) of same opioid if possible should be~10 20% of total daily opioid dose
OPIOID CONVERSIONS 1. Converting Short acting Long Acting (IR SR) when pain is well controlled *Use for : CHRONIC pain Pts on scheduled IR opioids pain that recurs before the next dose PP: Can use equianalgesic
Considerations when Using Controlled Substances to Treat Chronic Pain
Considerations when Using Controlled Substances to Treat Chronic Pain By Mary-Beth F. Plum, Pharm.D. Impact of Chronic Pain Acute pain is the body s response to environmental dangers, and it helps protect
A HISTORICAL PERSPECTIVE ON HUMAN ABUSE LIABILITY STUDIES. Donald R Jasinski, MD
A HISTORICAL PERSPECTIVE ON HUMAN ABUSE LIABILITY STUDIES Donald R Jasinski, MD Origin of methods Modify morphine molecule Develop a selective analgesic lacking abuse potential Reduce public health and
MUSC Opioid Analgesic Comparison Chart
MUSC Opioid Analgesic Comparison Chart Approved by the Pharmacy and Therapeutics Committee (February 2006, November 2009, March 2010, December 2011) Prepared by the MUSC Department of Pharmacy Services
Massachusetts Substance Abuse Policy and Practices. Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District
Massachusetts Substance Abuse Policy and Practices Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District November 2014 Substance Abuse and Addiction National and State opioid abuse
Abstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
Nurses Self Paced Learning Module on Pain Management
Nurses Self Paced Learning Module on Pain Management Dominican Santa Cruz Hospital Santa Cruz, California Developed by: Strategic Planning Committee Dominican Santa Cruz Hospital 1555 Soquel Drive Santa
Southlake Psychiatry. Suboxone Contract
Suboxone Contract Thank you for considering Southlake Psychiatry for your Suboxone treatment. Opiate Addiction is a serious condition for which you may find relief with Suboxone treatment. In order to
The ABCs of Medication Assisted Treatment
The ABCs of Medication Assisted Treatment J E F F R E Y Q U A M M E, E X E C U T I V E D I R E C T O R C O N N E C T I C U T C E R T I F I C A T I O N B O A R D The ABCs of Medication Assisted Treatment
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: Frenchay 0117 340 6692 Southmead 0117 323
How To Understand The Health Effects Of Prescription Drugs
Miami-Dade, Broward and Palm Beach Counties, Florida Trends of Nonmedical Prescription Drug Misuse in Miami-Dade, Broward, Palm Beach Counties, and the State of Florida: 2010 James N. Hall 1 ABSTRACT The
Blueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
Review of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
Acute & Chronic Pain Management (requiring opioid analgesics) in Patients Receiving Pharmacotherapy for Opioid Addiction
Acute & Chronic Pain Management (requiring opioid analgesics) in Patients Receiving Pharmacotherapy for Opioid Addiction June 9, 2011 Tufts Health Care Institute Program on Opioid Risk Management Daniel
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
Mid-Level Practitioners Authorization by State
Mid-Level Practitioners Authorization by State Pursuant to Title 21, Code of Federal Regulations, Section 1300.01(b28), the term mid-level practitioner means an individual practitioner, other than a physician,
ORDER OF EMERGENCY SUSPENSION OF LICENSE
Final Order No. DOH-I -2295- QA FILED DATE -R AA Department of Health STATE OF FLORIDA DEPARTMENT OF HEALTH In Re: Emergency Suspension of the License of By Deputy Agency Clerk ORDER OF EMERGENCY SUSPENSION
One example: Chapman and Huygens, 1988, British Journal of Addiction
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
10/19/15. Stephen Loyd, M.D., F.A.C.P Healthy Kingsport Meadowview Convention Center Kingsport, Tennessee October 17, 2015
Stephen Loyd, M.D., F.A.C.P Healthy Kingsport Meadowview Convention Center Kingsport, Tennessee October 17, 2015 Receives no commercial support, in any form, from pharmaceutical companies or anyone else
2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov
OHIO AUTOMATED RX REPORTING SYSTEM 2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov OHIO AUTOMATED RX REPORTING SYSTEM What is OARRS? To address the growing misuse and diversion
IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act
IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This
How To Get A Tirf
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under This Program Abstral (fentanyl)
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
Drug Abuse & Alcoholism
Drug Abuse & Alcoholism PRESENTED BY: ROBERT SWOTINSKY M D FOR MEDICAL EXAMINER COURSE 978-337-4479 P [email protected] Drugs, Drinking, and Driving CMV drivers - more fatalities than any other occupation.
11/26/2012. Implementation of Florida s PDMP. Disclosure
Implementation of Florida s PDMP Rebecca R. Poston Program Manager December 1, 2012 Disclosure I have no vested interest in or affiliation with any corporate organizations offering financial support or
What Is a Prescriber s Role in Preventing the Diversion of Prescription Drugs?
What Is a Prescriber s Role in Preventing the Diversion of Prescription Drugs? 2 CONTENT SUMMARY Drug diversion is the illegal distribution or abuse of prescription drugs or their use for unintended purposes.
Pharmacology of Opiates. Steve Hanson Associate Commissioner NYS OASAS
Pharmacology of Opiates Steve Hanson Associate Commissioner NYS OASAS Neurotransmitter-receptor receptor interactions To transmit instructions to cells, neurotransmitters interact with their receptors.
\ ~untv Administrator's Sionature:
BOARD OF COUNTY COMMISSIONERS DATE: September 23, 2014 AGENDA ITEM NO. _3{:;, Consent Agenda D Regular Agenda D Public Hearing ~ \ ~untv Administrator's Sionature: Subject: Public Hearing for a Proposed
Prescription Opioid Overdose & Misuse in Oregon
Prescription Opioid Overdose & Misuse in Oregon Mel Kohn, MD MPH Public Health Director and State Public Health Officer Oregon Health Authority Oregon In-State Policy Workshop NGA Policy Academy: Reducing
Opioid/Opiate Dependent Pregnant Women
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
Case Studies: Acute pain management in patients with opioid addiction. Shannon Levesque, PharmD Clinical Pharmacist
Case Studies: Acute pain management in patients with opioid addiction Shannon Levesque, PharmD Clinical Pharmacist Disclosure I have no financial relationships with industry to disclose Objectives Misconceptions
punishment increased 1 degree. If force used, degree felony (3)(A) other opium and opiates Delivery of Penalty 1 Substance 180days-2yrs; <$10,000
PENALTY GROUP OFFENSES/PENALTIES ENHANCEMENTS/BENEFIT RESTRICTIONS 481.102 Penalty Group 1 (1) Opiates (2) Opium derivatives: e.g., codeine compounds, morphine compounds, heroin 481.112 Manufacture or
HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
